These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21515629)

  • 1. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.
    Chauffier K; Salliot C; Berenbaum F; Sellam J
    Rheumatology (Oxford); 2012 Jan; 51(1):60-8. PubMed ID: 21515629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic interventions for fatigue in rheumatoid arthritis.
    Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients.
    van Hoogmoed D; Fransen J; Repping-Wuts H; Spee L; Bleijenberg G; van Riel PL
    Scand J Rheumatol; 2013; 42(1):15-9. PubMed ID: 22992002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is improvement of fatigue in rheumatoid arthritis a proper effect of biologics?
    Ines M; Aicha BT; Leila R; Ali M; Thouraya G; Rawdha T; Olfa S; Leila A
    Rom J Intern Med; 2021 Mar; 59(1):58-65. PubMed ID: 33010144
    [No Abstract]   [Full Text] [Related]  

  • 7. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing face of septic arthritis complicating rheumatoid arthritis in the era of biotherapies. Retrospective single-center study over 35years.
    Dubost JJ; Pereira B; Tournadre A; Tatar Z; Couderc M; Soubrier M
    Joint Bone Spine; 2017 Jan; 84(1):47-50. PubMed ID: 27269649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Druce KL; Jones GT; Macfarlane GJ; Basu N
    Rheumatology (Oxford); 2015 Jun; 54(6):964-71. PubMed ID: 25313148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers.
    de La Forest Divonne M; Gottenberg JE; Salliot C
    Joint Bone Spine; 2017 Mar; 84(2):133-140. PubMed ID: 27341745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
    Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
    Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F; Michaud K
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue in rheumatoid arthritis reflects pain, not disease activity.
    Pollard LC; Choy EH; Gonzalez J; Khoshaba B; Scott DL
    Rheumatology (Oxford); 2006 Jul; 45(7):885-9. PubMed ID: 16449363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.